Q-omics provides the consensus-scored PRR5-ARHGAP8 profile across patient tissues and cancer cell-line models. PRR5-ARHGAP8 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRR5-ARHGAP8 is differentially expressed in 14, with the highest sampling consensus in STAD. Additionally, PRR5-ARHGAP8 RNA expression shows 14,087 significant gene co-expression associations, with the highest sampling consensus in KICH. Together, these results highlight KIRC, STAD, and KICH as cancer lineages where PRR5-ARHGAP8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRR5-ARHGAP8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRR5-ARHGAP8 survival associations across molecular data types. PRR5-ARHGAP8 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRR5-ARHGAP8 RNA expression–survival associations across cancer types. High PRR5-ARHGAP8 expression shows unfavorable associations in ACC, CESC, PAAD and KICH, but favorable associations in KIRC and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRR5-ARHGAP8 RNA expression.
This table summarizes PRR5-ARHGAP8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRR5-ARHGAP8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRR5-ARHGAP8 shows lower tumor expression in KIRC and higher tumor expression in STAD, BLCA, COAD, HNSC and BRCA. The STAD box plot shows higher PRR5-ARHGAP8 RNA expression in tumor versus normal tissue (log2 FC = +0.480, t-test p < 0.001).
This table shows molecular features associated with PRR5-ARHGAP8 in patient tissues and cancer cell lines. In patient samples, PRR5-ARHGAP8 shows the broadest associations at the RNA and protein expression levels, with KICH recurring as the lineage with the largest associated feature set. In cancer cell lines, PRR5-ARHGAP8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OVARY.
